Dovramilast（CAS No.:340019-69-4） is a highly promising drug for the treatment of airway diseases such as COPD and asthma.

Dovramilast is a novel and highly effective drug used in the treatment of chronic obstructive pulmonary disease (COPD) and asthma. It is a selective phosphodiesterase 4 (PDE4) inhibitor that works by blocking the enzyme PDE4, which is responsible for the breakdown of cyclic adenosine monophosphate (cAMP) in inflammatory cells.

Dovramilast has demonstrated its efficacy as an anti-inflammatory agent in preclinical studies. Several clinical trials have also shown that this drug is well-tolerated and can significantly improve lung function and reduce exacerbations in patients with COPD.

Furthermore, Dovramilast has shown a potent anti-inflammatory effect in reducing symptoms such as coughing, wheezing, and shortness of breath in patients with asthma. It has been demonstrated that Dovramilast reduces eosinophil recruitment and activation, which are associated with airway inflammation and obstruction in asthmatic patients.

The unique mechanism of action of Dovramilast makes it a promising drug for the treatment of airway diseases. In addition, its oral administration and good safety profile make it an attractive option for long-term therapy.



1. Rennard SI, Calverley PM, Goehring UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18.

2. Spina D. PDE4 inhibitors: current status and potential for the treatment of asthma. Drugs. 2008;68(5): 803–816.

3. Yamasaki K, Suzuki K, Ichinose M. Phosphodiesterase 4 inhibitors in the treatment of COPD and asthma: where are we now and where do we go from here? Pharmacol Ther. 2019;204:107398.

In conclusion, Dovramilast is a highly promising drug for the treatment of airway diseases such as COPD and asthma. Its unique mechanism of action and good safety profile make it an attractive option for long-term therapy.